Coronary Intervention & Surgery

People with severe but stable ischemic heart disease don’t benefit any more from invasive CV procedures than they do from optimal medical therapy and lifestyle changes alone, according to results from the highly anticipated ISCHEMIA trial.

Research published in JAMA Nov. 12 suggests that, despite the Organ Procurement and Transplant Network’s overhaul of the U.S. heart allocation system in 2018, CV transplant programs still suffer from variability in survival benefit and a lack of standardized guidelines for ranking candidates.

Women face a greater risk of bleeding and hemorrhagic stroke after PCI than men, according to a new subgroup analysis of the GLOBAL LEADERS trial.

A 61-year-old patient at the West Virginia University Heart and Vascular Institute is the first in the state to receive a successful heart transplant, WVU reported Nov. 10.

Multiarterial CABG was linked to lower rates of long-term mortality, reintervention and MI than single-arterial CABG in a recent study of heart patients, suggesting the multiarterial approach is underused in contemporary practice.

CMS has finalized a rule that states, come Jan. 1, it will begin paying for certain PCIs performed at ambulatory surgical centers in the U.S.

Two studies reach conflicting conclusions while underscoring the need for best practice guidelines to fill the current vacuum.

Hackensack University Medical Center is the first practice in the U.S. to successfully perform heart surgeries using Abiomed’s Impella 5.5 LVAD.

Children’s hospitals across the U.S. are backing a national effort by the Pediatric Congenital Heart Association to improve transparency in the reporting of cardiac surgical outcomes.

Frailty assessments are a good value for their money in older patients considering CABG, according to a study published in the Canadian Journal of Cardiology, but a limited geriatric consultation workforce could curb that benefit in real-life practice.

An increase in public reporting of aortic valve surgery outcomes has been tied to a decrease in AVR access for patients with infective endocarditis—the unintended consequence of a push for greater transparency in healthcare.

Results from the late-breaking TWILIGHT trial suggest that, among high-risk patients who have undergone PCI and completed three months of dual antiplatelet therapy, it’s safer to continue treatment with ticagrelor alone rather than add aspirin to that cocktail.